Pharma news on AI's role in drug development, new FDA/EMA guidance, clinical advances, MFN pricing agreements, and ongoing quality control challenges.

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging, at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.

Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make Breast cancer progress, and Keytruda gets under your skin.

This article takes a look at the developing use of AI in pharmaceutical development and manufacturing.

The go-ahead for Novartis’ oral treatment marks a new option for patients with spontaneous urticaria who remain symptomatic despite antihistamine therapy.

This review of the nitrosamines contamination problem in pharmaceuticals takes a look at how the crisis started and developed.

Sept. 30 marked 61 days since July 31, one day past the timeframe President Donald Trump had set forth for companies to lower prescription drug prices in the United States.

A draft reflection paper on patient experience data is up for public consultation until Jan. 31, 2026.

FDA's Center for Biologics Evaluation and Research has released updated draft recommendations for sponsors of cell therapies, gene therapies, and tissue products.

In this continuation of a three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

Pharmaceutical Technology® spoke with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, to learn more about Crown Bioscience’s collaboration with Medicines Discovery Catapult on a new development platform for radiopharmaceuticals.

Your weekly news hub for biopharma trends, FDA regulations, M&A deals, supply chain insights, drug development innovations from BIO-Europe, and more.

David McErlane, Group President of Biologics at Catalent, shares how integrated expertise in biologics helps simplify complexity, accelerate development, and deliver therapies to patients faster.

The 100% tariff on imported drugs will pressure pharma companies to build manufacturing sites in the US or face significant costs.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates, and Siegfried Schmitt, PhD, Parexel, answer questions on the use of real-world evidence for both small-molecule and large-molecule drug development. In addition, they tackle a question on supply chain security problems that arise during transportation of pharmaceutical goods.